Sarepta Therapeutics (SRPT) Current Assets (2010 - 2026)

Sarepta Therapeutics has reported Current Assets for 17 years, with the latest figure at $2.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 5.04% year-over-year to $2.3 billion; the trailing twelve-month figure through Mar 2026 stood at $2.3 billion (down 5.04% YoY), and the FY2025 full-year result was $2.5 billion, down 17.42% from the prior year.
• Current Assets for Q1 2026 stood at $2.3 billion, down from $2.5 billion in the prior quarter.
• The five-year high for Current Assets was $3.1 billion in Q4 2024, with the low at $2.3 billion in Q1 2026.
• Average Current Assets over 5 years is $2.6 billion, with a median of $2.5 billion recorded in 2025.
• Year-over-year, Current Assets increased 20.16% in 2022 and declined 17.42% in 2025.
• Tracing SRPT's Current Assets over 5 years: stood at $2.6 billion in 2022, then increased by 0.84% to $2.6 billion in 2023, then gained by 19.16% to $3.1 billion in 2024, then dropped by 17.42% to $2.5 billion in 2025, then declined by 8.99% to $2.3 billion in 2026.
• The last three Current Assets figures came in at $2.3 billion (Q1 2026), $2.5 billion (Q4 2025), and $2.7 billion (Q3 2025), per Business Quant data.

Peer Comparison